News & Updates
Showing Pharmacy articles
Showing
Show Multimedia Only

Enzalutamide-ADT a win for biochemically recurrent prostate cancer
27 Oct 2025
byAudrey Abella
In the final overall survival (OS) analysis of the phase III EMBARK trial, the combination of enzalutamide and androgen deprivation therapy (ADT; leuprolide acetate) delivers a significant OS benefit in men with high-risk biochemically recurrent (hrBCR) prostate cancer without evidence of metastases on conventional imaging.








